Biopharma Science Industry Insights

Scientists wearing white coats looking at camera with arms crossed.

Industry Insight

Cautious Optimism in a Year of Change: Insights From the 2025 Horizons Report

In a year defined by volatility and rapid transformation, the latest Horizons Report from CRB Group offers a revealing look at how life sciences organizations are navigating uncertainty while maintaining cautious optimism.

Illustration of synthetic mRNA structure for cell-free DNA synthesis.

Industry Insight

Unlocking mRNA Therapeutics: Cell-Free DNA Synthesis Is Powering the AI Era of Genetic Medicine

Discover how cell-free DNA synthesis can accelerate mRNA vaccines and therapies, enhancing production efficiency and lowering contamination risks.

A scientist holding a tablet with a hologram floating above it, that contains a diagram of the human body and a large icon reading "AI".

Industry Insight

The Bottleneck in Biotech Isn’t AI Technology — It’s Trust

Trust is often a major barrier to companies integrating AI tools. Learn how better data governance can improve confidence.

Mark Fish presenting his keynote talk, in front of a large screen.

Industry Insight

Building the Automated Digital Lab of the Future

Discover the power of the automated digital lab for furthering scientific research and the importance of open collaboration.

A digital illustration of a cell meeting an encapsulated cell therapy particle.

Industry Insight

Where Promising Drugs Fail: Rethinking How We Deliver Advanced Therapies

Discover how advanced drug delivery technologies are revolutionizing biotech, enabling safe, targeted cell therapy with fewer side effects.

Scientists wearing PPE working in ReiThera's bioprocessing facility.

Industry Insight

From Platform Engineering to Next-Generation Therapies: The ReiThera Story

In this article, ReiThera's scientific and operational leaders discuss ReiThera’s proprietary platforms, process development strategy and its evolving role as a CDMO partner in the advanced therapies landscape.

Digital 3D model of a protein structure representing data-driven proteomics research.

Industry Insight

Beyond Mutations: Inside Immuto’s Quest To Decode Disease Structure

Immuto Scientific’s structural surfaceomics platform reveals how wild-type proteins adopt disease-specific shapes that drive pathology. Immuto identifies previously invisible drug targets and designs conformation-selective therapies.

Illustration of an orange cancer cell being targeted by light blue immune cells.

Industry Insight

Lipid-Based Systems’ Potential To Transform CAR T Therapy for Solid Tumors

In this interview, Dr. Kelemen discusses the advantages of lipid-based delivery systems and their potential to expand the reach of CAR T-cell therapies into solid tumor indications.

Blue drug capsule with lower half made from computer network and the upper half containing small human brains.

Industry Insight

AI-Powered Platforms Are Making Complex Data Usable for Drug Discovery

In this interview, we explore how Sonrai is advancing reproducible science, enabling cross-disciplinary collaboration and shaping the future of AI-powered drug discovery.